Antibody-drug conjugates for cancer therapy: An up-to-date review on the chemistry and pharmacology

Gholap, Amol D.; Gupta, Juhi S.; Kamandar, Pallavi A.; Banchhod, Gauri V.; Hatvate, Navnath T.

doi:10.1016/bs.coac.2023.02.007

Cited by 4 publications

(2 citation statements)

References 222 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overuse of azole for treatment is one of the reasons for the development of these resistant species ( 175 ). The fungi have developed resistance mechanisms involving modifications of the drug targets, cellular pathways alterations, especially in sterol biosynthesis, reduction in the intercellular concentration of the target enzyme, and overexpression of the antifungal drug targets ( 176 ). The activation of the stress response signaling and overexpression of the efflux pump protein are also covered.…”

Section: Novel Approaches To Drug Deliverymentioning

confidence: 99%

Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review

Faiyazuddin,

Sophia,

Ashique

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

The outbreak of a fatal black fungus infection after the resurgence of the cadaverous COVID-19 has exhorted scientists worldwide to develop a nutshell by repurposing or designing new formulations to address the crisis. Patients expressing COVID-19 are more susceptible to Mucormycosis (MCR) and thus fall easy prey to decease accounting for this global threat. Their mortality rates range around 32-70% depending on the organs affected and grow even higher despite the treatment. The many contemporary recommendations strongly advise using liposomal amphotericin B and surgery as first-line therapy whenever practicable. MCR is a dangerous infection that requires an antifungal drug administration on appropriate prescription, typically one of the following: Amphotericin B, Posaconazole, or Isavuconazole since the fungi that cause MCR are resistant to other medications like fluconazole, voriconazole, and echinocandins. Amphotericin B and Posaconazole are administered through veins (intravenously), and isavuconazole by mouth (orally). From last several years so many compounds are developed against invasive fungal disease but only few of them are able to induce effective treatment against the micorals. Adjuvant medicines, more particularly, are difficult to assess without prospective randomized controlled investigations, which are challenging to conduct given the lower incidence and higher mortality from Mucormycosis. The present analysis provides insight into pathogenesis, epidemiology, clinical manifestations, underlying fungal virulence, and growth mechanisms. In addition, current therapy for MCR in Post Covid-19 individuals includes conventional and novel nano-based advanced management systems for procuring against deadly fungal infection. The study urges involving nanomedicine to prevent fungal growth at the commencement of infection, delay the progression, and mitigate fatality risk.

show abstract

Section: Novel Approaches To Drug Deliverymentioning

confidence: 99%

Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review

Faiyazuddin,

Sophia,

Ashique

et al. 2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Antibody–drug conjugates (ADCs) are currently among the most promising drug classes in oncology because of their ability to deliver cytotoxic agents to specific tumor sites, combining the selectivity of monoclonal antibodies (mAbs) and the efficacy of chemotherapeutic drugs. − Cancer is a major global health threat, causing millions of fatalities yearly. , Chemotherapies based on cytotoxic drugs have been the main strategy for treating of a wide assortment of cancers for decades. , Cytotoxic drugs include a large variety of compounds such as alkylating agents, antimetabolites, antitumor antibiotics, topoisomerase and mitotic inhibitors, and corticosteroids among many others. − Most of these antitumor drugs, however, exhibit low therapeutic index and cause severe side effects due to nonspecific drug exposure to off-target tissues . To address these challenges, intense research has been carried out, aimed at developing novel cancer therapeutics with better targeting ability and less harmful side effects.…”

Section: Introductionmentioning

confidence: 99%

The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

Sasso,

Tenchov,

Bird

et al. 2023

Bioconjugate Chem.

View full text Add to dashboard Cite

Antibody–drug conjugates (ADCs) are targeted immunoconjugate constructs that integrate the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, minimizing damage to healthy cells and reducing systemic toxicity. Their design allows for higher doses of the cytotoxic drug to be administered, potentially increasing efficacy. They are currently among the most promising drug classes in oncology, with efforts to expand their application for nononcological indications and in combination therapies. Here we provide a detailed overview of the recent advances in ADC research and consider future directions and challenges in promoting this promising platform to widespread therapeutic use. We examine data from the CAS Content Collection, the largest human-curated collection of published scientific information, and analyze the publication landscape of recent research to reveal the exploration trends in published documents and to provide insights into the scientific advances in the area. We also discuss the evolution of the key concepts in the field, the major technologies, and their development pipelines with company research focuses, disease targets, development stages, and publication and investment trends. A comprehensive concept map has been created based on the documents in the CAS Content Collection. We hope that this report can serve as a useful resource for understanding the current state of knowledge in the field of ADCs and the remaining challenges to fulfill their potential.

show abstract

Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies

Mesut,

Al-Mohaya,

Gholap

et al. 2024

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

Antibody-drug conjugates for cancer therapy: An up-to-date review on the chemistry and pharmacology

Cited by 4 publications

References 222 publications

Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review

Virulence traits and novel drug delivery strategies for mucormycosis post-COVID-19: a comprehensive review

The Evolving Landscape of Antibody–Drug Conjugates: In Depth Analysis of Recent Research Progress

Demystifying the potential of lipid-based nanocarriers in targeting brain malignancies

Contact Info

Product

Resources

About